#United States #Delaware #Amgen #Harbour BioMed #Antibody Patent

Harbour BioMed Achieves Landmark Legal Victory Against Amgen

In a significant legal development, Harbour BioMed has won a pivotal patent infringement case against Amgen and its subsidiary Teneobio. This momentous ruling, delivered by a jury in the U.S. District Court for Delaware, has important implications for the patent landscape in the global antibody market.

The case, which dates back to 2021 when it was initiated by Harbour Antibodies, centered around allegations that Amgen had infringed upon Harbour's innovative antibody discovery platform. This platform was pioneered by Professor Frank Grosveld, one of the founders of Harbour Antibodies. The jury's verdict unequivocally affirmed the validity of the Grosveld Patent, concluding that Amgen's infringement was willful and awarding Harbour a total of $20.2 million in damages.

This verdict is noteworthy not just for the damages awarded, but also for what it signifies about intellectual property rights in the biopharmaceutical industry. The jury's findings give Harbour the potential to request that the court triples the damages, which could increase the total to $60.6 million.

Dr. Jingsong Wang, the Chairman and CEO of Harbour BioMed, hailed the verdict as a triumph for innovation, emphasizing that it underscores the importance of respecting scientific contributions regardless of corporate size. “This is an epic victory for Harbour BioMed, reaffirming the company as the true innovator behind this transformative technology,” Dr. Wang stated, celebrating the jury's clear message in favor of scientific integrity.

Background on the Case

The origins of the case lie in an ongoing struggle to secure patent rights crucial for biopharmaceutical advancements. As the case unfolded, Harbour BioMed adopted a strategic dual approach: they actively pursued claims on one particular patent while preparing for an appeal on another. This approach not only maintained the momentum required to litigate effectively but also safeguarded broader claims regarding Harbour's innovation.

During a trial that commenced on June 8, 2026, the jury deliberated for just three hours before issuing its unanimous verdict, finding all key claims in Harbour’s favor. The case marks a turning point in how patent issues may be handled in future cases involving major players in the biopharmaceutical arena, highlighting the importance of robust legal strategies and clear communication of scientific achievements.

Future Implications

Looking ahead, Harbour BioMed is set to continue its efforts in defending its patent rights with a keen focus on another patent that has the potential for even greater financial repercussions. This proactive stance indicates the company's commitment to safeguarding its intellectual property and maximizing innovations that contribute to global health advancements.

The case against Amgen represents a profound industry precedent, shaping expectations on how patent infringements may be viewed and adjudicated in the increasingly competitive field of biopharmaceuticals. With this recent victory, Harbour BioMed not only strengthens its own position but also sets a compelling example for other innovators in the sector, reaffirming that relentless pursuit of intellectual property protections can yield remarkable results.

About Harbour BioMed

Harbour BioMed operates as a global biopharmaceutical entity dedicated to discovering and developing novel antibody therapeutics across multiple therapeutic areas, including immunology and oncology. The company leverages its proprietary Harbour Mice technology to generate fully human monoclonal antibodies and continues to innovate with platforms that integrate advanced technologies, including artificial intelligence. Through a robust pipeline and strategic collaborations, Harbour BioMed is positioning itself as a leader not only in scientific discovery but also in the protection of essential intellectual property rights that facilitate progress in medicine.

For more information about Harbour BioMed’s offerings and updates, visit Harbour BioMed's official website.